Overview

A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects

Status:
COMPLETED
Trial end date:
2025-04-07
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind, single-dose, placebo-controlled phase I clinical trial. This study plans to conduct three dose groups of dose 1, dose 2, and dose 3. A total of 32 healthy subjects were planned to be enrolled.
Phase:
PHASE1
Details
Lead Sponsor:
Chengdu Suncadia Medicine Co., Ltd.